it is concluded that the behavioral effects and the antiparkinsonian properties of ergot drugs can to a large extent be explained by the hypothesis that ergot drugs act at various dopamine receptor sites in the brain as partial agonists , the ratio of agonist-antagonist activity varying from one dopamine receptor population to another .
C0004927
behavioral
C0006104
brain